Article
Oncology
Claire van Vliet, Chris Dickhoff, Idris Bahce, Anton F. Engelsman, Sayed M. S. Hashemi, Cornelis J. A. Haasbeek, Anna M. E. Bruynzeel, Miguel A. Palacios, Annemarie Becker-Commissaris, Berend J. Slotman, Suresh Senan, Famke L. Schneiders
Summary: This study investigated treatment patterns for adrenal metastases using surgery or SABR at a single institution. The number of patients undergoing SABR doubled since 2016, while the numbers undergoing surgery remained unchanged. Both treatments showed low rates of acute toxicity and similar survival outcomes.
RADIOTHERAPY AND ONCOLOGY
(2022)
Review
Medicine, General & Internal
Meritxell Molla, Julen Fernandez-Plana, Santiago Albiol, Constantino Fondevila, Ivan Vollmer, Carla Cases, Angeles Garcia-Criado, Jaume Capdevila, Carles Conill, Yliam Fundora, Carlos Fernandez-Martos, Estela Pineda
Summary: The prognosis for oligometastatic colorectal cancer has improved due to recent advances in new techniques and approaches such as new surgical procedures, better systemic treatments, percutaneous ablation, and stereotactic body radiation therapy. Factors to consider when deciding on the best approach include tumor factors, patient factors, and physician factors. These advances have presented challenges and opportunities for oncologic multidisciplinary teams to treat patients with limited liver and lung metastases.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Oncology
Zhi Wen, Li Wang, Jing Huang, Yang Liu, Cai-xia Chen, Chong-jian Wang, Lin-lin Chen, Xue-song Yang
Summary: This study compared the outcomes of partial nephrectomy (PN) and ablation (AT) for the treatment of small solitary renal tumors. The results showed that compared to PN, AT had shorter hospital stays, shorter operating times, lower risks of postoperative creatinine increases and glomerular filtration rate decreases, less postoperative new-onset chronic kidney disease, and less intraoperative blood loss. However, the risk of local recurrence was higher in the AT group, while the risk of distant metastasis was higher in the PN group. Overall survival, postoperative dialysis rate, and tumor-specific survival were not different between the two groups.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Bichun Xu, Xianzhi Zhao, Di Chen, Wenjuan Zhao, Xiaoyan Wang, Changhua Ding, Zhiyong Yuan, Huojun Zhang
Summary: This study reports the feasibility and effectiveness of stereotactic body radiation therapy (SBRT) in the treatment of adrenal gland metastases (AGMs) from liver cancer. The results suggest that SBRT is a safe and effective technique for treating AGMs, especially in patients with smaller tumors.
Article
Urology & Nephrology
Gaelle Margue, Clement Michiels, Clement Allenet, Laure Dupitout, Solene Ricard, Eva Jambon, Peggy Blanc, Eric Alezra, Vincent Estrade, Gregoire Capon, Franck Bladou, Gregoire Robert, Nicolas Grenier, Jean-Christophe Bernhard
Summary: This study retrospectively evaluated the feasibility of salvage robot-assisted partial nephrectomy (sRAPN) after ablative therapies (AT) failure. The results showed that although these surgeries were difficult and associated with a high complication rate, they had good functional and oncological outcomes.
MINERVA UROLOGY AND NEPHROLOGY
(2022)
Article
Oncology
Sean All, Aurelie Garant, Raquibul Hannan
Summary: Recent data suggests that a subgroup of mRCC patients with oligometastatic disease may benefit from aggressive local therapy, with the potential of high local control efficacy and improved survival using SAbR. Large prospective trials are needed to integrate SAbR with systemic therapies to harness the optimal benefit for this patient population.
SEMINARS IN RADIATION ONCOLOGY
(2021)
Article
Acoustics
Huohu Zhong, Zecheng Wang, Yingchao Liu, Helin Ke, Piaopiao Liu, Xihua Lian, Zhenhong Xu
Summary: This meta-analysis found that ultrasound-guided percutaneous ablation (US-PA) is an effective and safe treatment for adrenal metastases. The results showed good outcomes in terms of technical success rate, overall survival, and local tumor control.
JOURNAL OF ULTRASOUND IN MEDICINE
(2023)
Article
Oncology
Savio Domenico Pandolfo, Davide Loizzo, Alp T. Beksac, Ithaar Derweesh, Antonio Celia, Lorenzo Bianchi, Jeffrey Elbich, Giovanni Costa, Umberto Carbonara, Giuseppe Lucarelli, Clara Cerrato, Margaret Meagher, Pasquale Ditonno, Lance J. Hampton, Giuseppe Basile, Fernando J. Kim, Riccardo Schiavina, Umberto Capitanio, Jihad Kaouk, Riccardo Autorino
Summary: This study compared the outcomes of robot-assisted partial nephrectomy (RAPN) and percutaneous thermal ablation (PTA) in the treatment of renal tumors cT1 in solitary kidney. The results showed that there were no significant differences in surgical, functional, and oncological outcomes between the two methods, but PTA may carry a higher risk of recurrence and may require retreatment.
Review
Urology & Nephrology
Arighno Das, Daniel D. D. Shapiro, Juliana K. K. Craig, E. Jason Abel
Summary: Cytoreductive nephrectomy is accepted as standard treatment for selected patients with mRCC due to improved survival. Novel systemic therapies have shown better outcomes compared to interferon-α, but some controversial results exist. The optimal timing and patient selection for surgery need to be determined as systemic therapies continue to evolve. This review explores the history, controversial results, and future perspectives of cytoreductive nephrectomy in managing mRCC.
NATURE REVIEWS UROLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Gregoire Cazalas, Clement Klein, Gilles Piana, Eric De Kerviler, Afshin Gangi, Philippe Puech, Cosmina Nedelcu, Remi Grange, Xavier Buy, Marc-Antoine Jegonday, Pierre Bigot, Charles Karim Bensalah, Victor Gaillard, Geraldine Pignot, Philippe Paparel, Lionel Badet, Clement Michiels, Jean Christophe Bernhard, Olivier Rouviere, Nicolas Grenier, Clement Marcelin
Summary: Percutaneous-guided thermal ablation and robotic-assisted partial nephrectomy are effective treatments for T1b renal cancer; however, thermal ablation has a higher local recurrence rate.
EUROPEAN RADIOLOGY
(2023)
Article
Oncology
James A. Kavanaugh, Matthew B. Spraker, Sai Duriseti, Franco Basarabescu, Alex Price, Murty Goddu, Nels Knutson, Michael Prusator, Clifford Robinson, Thomas Mazur
Summary: This study reports the dosimetric endpoints achieved for Lattice stereotactic body radiation therapy (SBRT) plans delivering 20 Gy in 5 fractions to the periphery of a tumor. The results show that the OAR sparing and target coverage planning objectives were achieved, and the conformity of the 20 Gy isodose line significantly improved throughout the study.
RADIOTHERAPY AND ONCOLOGY
(2022)
Article
Urology & Nephrology
Braden Millan, Rodney H. Breau, Bimal Bhindi, Ranjeeta Mallick, Simon Tanguay, Antonio Finelli, Luke T. Lavallee, Frederic Pouliot, Ricardo Rendon, Alan I. So, Lucas Dean, Jean-Baptiste Lattouf, Naveen S. Basappa, Anil Kapoor
Summary: This study compared the efficacy of percutaneous ablation therapy and partial nephrectomy in the treatment of T1a renal cancer. The results showed that partial nephrectomy had better recurrence-free survival, while there was no significant difference in overall survival.
JOURNAL OF UROLOGY
(2022)
Article
Oncology
Lin Xie, Han Qi, Fei Cao, Lujun Shen, Shuanggang Chen, Ying Wu, Tao Huang, Ze Song, Weijun Fan
Summary: The study retrospectively compared the efficacy and safety of surgical resection and thermal ablation for the treatment of adrenal metastases. Thermal ablation showed similar local progression-free survival and fewer complications, less blood loss, and shorter hospital stays compared to surgical resection.
INTERNATIONAL JOURNAL OF HYPERTHERMIA
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Alba Fiorentino, Fabiana Gregucci, Ilaria Bonaparte, Nicola Vitulano, Alessia Surgo, Rosario Mazzola, Antonio Di Monaco, Roberta Carbonara, Filippo Alongi, Tommaso Langialonga, Massimo Grimaldi
Summary: SABR has been used for the treatment of cardiac arrhythmias based on preclinical and clinical data, demonstrating it as a safe and effective noninvasive treatment approach with a good response time of 2-3 months. The treatment dose is crucial for efficacy, and clinical data support the feasibility, effectiveness, and safety of SABR for refractory ventricular arrhythmias.
Article
Oncology
Elysia K. Donovan, Feng Xie, Alexander V. Louie, William Chu, Shankar Siva, Anil Kapoor, Anand Swaminath
Summary: This study compares the cost-effectiveness of stereotactic body radiotherapy (SBRT) and radiofrequency ablation (RFA) in the non-surgical management of early stage renal cell carcinoma (RCC) in the Canadian healthcare system. The results show that, overall, SBRT is a cost-effective treatment option compared to RFA for RCC in Canada. This conclusion holds true for both larger tumors and smaller tumors.
CLINICAL GENITOURINARY CANCER
(2022)
Review
Urology & Nephrology
Sean Ong, Kenneth Chen, Jeremy Grummet, John Yaxley, Matthijs J. Scheltema, Phillip Stricker, Kae Jack Tay, Nathan Lawrentschuk
Summary: This article provides a summary and discussion of international guidelines, position statements, and consensus statements on focal therapy for prostate cancer. The lack of long-term randomized data for focal therapy is highlighted, and the need for high-quality clinical trials with robust outcomes is emphasized. The current consensus and position statements are heterogeneous, indicating a need for globally accepted guidelines for focal therapy planning and follow-up.
Article
Oncology
D. Berger, S. Van Dyk, L. Beaulieu, T. Major, T. Kron
Summary: This review highlights the emergence of brachytherapy tools and technologies over the past decade. Advances in soft-tissue imaging using magnetic resonance and ultrasound have greatly improved the planning of brachytherapy. Image-guided brachytherapy has led to the development of advanced applicators and the use of 3D printing for precise and reproducible implants. Improved dosimetry algorithms and dose optimization toolkits have enhanced the accuracy and efficiency of brachytherapy treatment planning. Traditional planning strategies remain relevant for validating new technologies. Overall, brachytherapy has evolved to become a high-tech and modern treatment while maintaining accessibility for all.
Article
Oncology
M. Swain, A. Budrukkar, A. Rembielak, T. Kron, J. P. Agarwal
Summary: Brachytherapy plays an irreplaceable role in certain cancers, but there are challenges in its preservation, accessibility, and distribution of care. There is an uneven distribution of brachytherapy facilities globally, especially in low and low-middle income countries. Bridging this gap requires a focus on uniform distribution, improving training, reducing costs, and generating evidence and guidelines.
Editorial Material
Oncology
A. Rembielak, A. Budrukkar, T. Kron
Article
Oncology
Nicholas W. Bucknell, Tomas Kron, Alan Herschtal, Nicholas Hardcastle, Louis Irving, Michael Macmanus, Gerard G. Hanna, Alisha Moore, Andrew Murnane, Shankar Siva, CHISEL coauthors
Summary: The study compares the effects of conventional radiation therapy (CRT) and stereotactic body radiation therapy (SBRT) in patients with inoperable early-stage non-small cell lung cancer. The results show that there is no significant difference in pulmonary function and walking distance between the two groups at 3 and 12 months after treatment.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Medicine, General & Internal
Daniel A. Goldstein, Gary M. Ginsberg, Dorit Hofnung-Gabbay, Richard De Abreu Lourenco, Herbert H. Loong, Boon Cher Goh, Kelvin K. W. Chan, Massimo Di Maio, Francesco Perrone, Peter S. Hall, Alona Zer, Eli Rosenbaum
Summary: The US FDA has recently approved new dosing options for immune checkpoint inhibitors, including extended-interval fixed dosing. The economic impact of this new dosing strategy compared to the standard dosing strategy is unknown.
Article
Medicine, Research & Experimental
Muhammad Ali, Simon Wood, David Pryor, Daniel Moon, Mathias Bressel, Arun A. Azad, Catherine Mitchell, Declan Murphy, Homi Zargar, Nick Hardcastle, Jamie Kearsley, Renu Eapen, Lih Ming Wong, Katharine Cuff, Nathan Lawrentschuk, Paul J. Neeson, Shankar Siva
Summary: This study aims to investigate the effectiveness of neoadjuvant stereotactic ablative body radiotherapy (SABR) with or without Pembrolizumab immunotherapy in patients with renal cell carcinoma. Twenty-six patients will be enrolled in this clinical trial and randomized to receive either SABR or SABR/Pembrolizumab. The results of this study will provide valuable insights for future clinical treatment of high-risk patients.
CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS
(2023)
Article
Oncology
Mathieu Gaudreault, David Chang, Nicholas Hardcastle, Lachlan McIntosh, Price Jackson, Tomas Kron, Cristian Udovicich, Michael S. Hofman, Shankar Siva
Summary: This study aims to determine the feasibility of Biology-guided radiotherapy (BgRT) treatment for renal cell carcinoma (RCC). It was found that over 60% of tumors in RCC patients were suitable for BgRT. However, the proximity of PET-avid organs such as the liver or the kidney may affect BgRT delivery.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
(2023)
Article
Oncology
Nicholas Bucknell, Nicholas Hardcastle, Roshini Gunewardena, Long Nguyen, Jason Callahan, David Ball, Lisa Selbie, Tomas Kron, Guy-Anne Turgeon, Michael S. Hofman, Shankar Siva
Summary: This study assessed the feasibility of using 68Ga-4D-V/Q PET/CT for dynamic imaging of lung function and adapting radiation therapy plans to changes in lung function during mid-treatment. The results showed that mid-treatment adaptation could reduce the dose to functional lung volumes in some NSCLC patients. The role of mid-treatment adaptation requires further investigation.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
(2023)
Editorial Material
Urology & Nephrology
Kenneth Chen, Sean Ong, Kandarpa Vasundhara, Chow Kit Mun, Isabella Williams, Ravindran Kanesvaran, John Yuen Shyi Peng, Arun A. Azad, Nathan Lawrentschuk
Article
Urology & Nephrology
David C. Homewood, Jonathan S. O'Brien, Todd Manning, Brian Kelly, Philip Chan, Ben Thomas, Nathan Lawrentschuk
Editorial Material
Urology & Nephrology
Siyu Huang, David C. Chen, Jordan Santucci, Declan G. Murphy, Nathan Lawrentschuk
Editorial Material
Urology & Nephrology
Gideon Ptasznik, Brian D. Kelly, Declan Murphy, Nathan Lawrentschuk, Veeru Kasivisvanathan, Mark Page, Sean Ong, Daniel Moon
Article
Oncology
Jelena Lukovic, Alisha J. Moore, Mark T. Lee, David Willis, Shahida Ahmed, Mohamed Akra, Eszter Hortobagyi, Tomas Kron, Daryl Lim Joon, Amy Liu, John Ryan, Melissa Thomas, Katelyn Wall, Iain Ward, Kirsty L. Wiltshire, Chris J. O'Callaghan, Rebecca K. S. Wong, Jolie G. Ringash, Karin Haustermans, Trevor Leong
Summary: This study aimed to investigate whether adding preoperative chemoradiation therapy could improve the survival rate in gastric cancer patients, and a comprehensive radiation therapy quality assurance program was implemented. The study found that ongoing education is necessary to ensure consistent quality during the entire study period.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Medicine, General & Internal
Eng-Siew Koh, Hui K. Gan, Clare Senko, Roslyn J. Francis, Martin Ebert, Sze Ting Lee, Eddie Lau, Mustafa Khasraw, Anna K. Nowak, Dale L. Bailey, Bradford A. Moffat, Greg Fitt, Rodney J. Hicks, Robert Coffey, Roel Verhaak, Kyle M. Walsh, Elizabeth H. Barnes, Richard De Abreu Lourenco, Mark Rosenthal, Lucas Adda, Farshad Foroudi, Arian Lasocki, Alisha Moore, Paul A. Thomas, Paul Roach, Michael Back, Robyn Leonard, Andrew M. Scott
Summary: FET-PET has the potential to impact adjuvant radiotherapy planning, differentiate between treatment-induced pseudoprogression and true tumor progression, and predict prognosis in glioblastoma management. The FIG study is a multicenter phase II study aiming to investigate the impact of FET-PET versus standard MRI on radiotherapy volume delineation and the accuracy and management impact of FET-PET in distinguishing pseudoprogression from true tumor progression.
